Lead Product(s): KSI-301
Therapeutic Area: Ophthalmology Product Name: KSI-301
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2020
New data from the ongoing Phase 1b study of KSI-301, its novel anti-VEGF antibody biopolymer conjugate, will be presented at the upcoming American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting.